Literature DB >> 23793364

Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States.

K Turaga1, E Levine, R Barone, R Sticca, N Petrelli, L Lambert, G Nash, M Morse, R Adbel-Misih, H R Alexander, F Attiyeh, D Bartlett, A Bastidas, T Blazer, Q Chu, K Chung, L Dominguez-Parra, N J Espat, J Foster, K Fournier, R Garcia, M Goodman, N Hanna, L Harrison, R Hoefer, M Holtzman, J Kane, D Labow, B Li, A Lowy, P Mansfield, E Ong, C Pameijer, J Pingpank, M Quinones, R Royal, G Salti, A Sardi, P Shen, J Skitzki, J Spellman, J Stewart, J Esquivel.   

Abstract

BACKGROUND: The American Society of Peritoneal Surface Malignancies (ASPSM) is a consortium of cancer centers performing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). This is a position paper from the ASPSM on the standardization of the delivery of HIPEC.
METHODS: A survey was conducted of all cancer centers performing HIPEC in the United States. We attempted to obtain consensus by the modified method of Delphi on seven key HIPEC parameters: (1) method, (2) inflow temperature, (3) perfusate volume, (4) drug, (5) dosage, (6) timing of drug delivery, and (7) total perfusion time. Statistical analysis was performed using nonparametric tests.
RESULTS: Response rates for ASPSM members (n = 45) and non-ASPSM members (n = 24) were 89 and 33 %, respectively. Of the responders from ASPSM members, 95 % agreed with implementing the proposal. Majority of the surgical oncologists favored the closed method of delivery with a standardized dual dose of mitomycin for a 90-min chemoperfusion for patients undergoing cytoreductive surgery for peritoneal carcinomatosis of colorectal origin.
CONCLUSIONS: This recommendation on a standardized delivery of HIPEC in patients with colorectal cancer represents an important first step in enhancing research in this field. Studies directed at maximizing the efficacy of each of the seven key elements will need to follow.

Entities:  

Mesh:

Year:  2013        PMID: 23793364     DOI: 10.1245/s10434-013-3061-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  46 in total

Review 1.  [Hyperthermic intraperitoneal chemotherapy].

Authors:  H Leebmann; P Piso
Journal:  Chirurg       Date:  2019-07       Impact factor: 0.955

2.  HIPEC Methodology and Regimens: The Need for an Expert Consensus.

Authors:  Aditi Bhatt; Ignace de Hingh; Kurt Van Der Speeten; Martin Hubner; Marcello Deraco; Naoual Bakrin; Laurent Villeneuve; Shigeki Kusamura; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2021-06-17       Impact factor: 5.344

Review 3.  The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan.

Authors:  Toshiyuki Kitai
Journal:  Surg Today       Date:  2020-11-13       Impact factor: 2.549

4.  Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement.

Authors:  Jason B Liu; Darryl Schuitevoerder; Charles C Vining; Yaniv Berger; Kiran K Turaga; Oliver S Eng
Journal:  Ann Surg Oncol       Date:  2020-07-29       Impact factor: 5.344

5.  Stratifying SLN incidence in intermediate thickness melanoma patients.

Authors:  James M Chang; Heidi E Kosiorek; Amylou C Dueck; Stanley P L Leong; John T Vetto; Richard L White; Eli Avisar; Vernon K Sondak; Jane L Messina; Jonathan S Zager; Carlos Garberoglio; Mohammed Kashani-Sabet; Barbara A Pockaj
Journal:  Am J Surg       Date:  2017-12-14       Impact factor: 2.565

Review 6.  Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7.

Authors:  Peter Cashin; Paul H Sugarbaker
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 7.  Metastatic Colorectal Cancer to the Peritoneum: Current Treatment Options.

Authors:  Nikolaos Vassos; Pompiliu Piso
Journal:  Curr Treat Options Oncol       Date:  2018-09-01

Review 8.  Peritoneal Metastases in Colorectal Cancer: Biology and Barriers.

Authors:  Lai Xue; Neil H Hyman; Kiran K Turaga; Oliver S Eng
Journal:  J Gastrointest Surg       Date:  2019-11-19       Impact factor: 3.452

9.  Can hyperthermic intraperitoneal chemotherapy efficiency be improved by blocking the DNA repair factor COP9 signalosome?

Authors:  Mathilde Feist; Xiaohua Huang; Joachim M Müller; Beate Rau; Wolfgang Dubiel
Journal:  Int J Colorectal Dis       Date:  2014-04-13       Impact factor: 2.571

10.  Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.

Authors:  Edward A Levine; John H Stewart; Perry Shen; Gregory B Russell; Brian L Loggie; Konstantinos I Votanopoulos
Journal:  J Am Coll Surg       Date:  2013-12-21       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.